Drugs / HS-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03906643 | Jul 2020 → Jan 2023 | cancer | Herbert Lyerly | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-03-06 | Aclaris Therapeutics, Inc. | Results Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa aclaristx.com ↗
The study did not meet its primary endpoint of change from baseline in inflammatory nodule/abscess count (AN) of zunsemetinib 50mg BID versus placebo at week 12. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-03-06 | Aclaris Therapeutics, Inc. | Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa aclaristx.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03906643 ↗ |
| Action | Inhibit | “HS-201 consists of a HSP90 inhibitor that binds competitively to the Hsp90 ATP binding domain” NCT03906643 ↗ |
| Modality | Diagnostic / imaging agent | “The product to be tested in this study, HS-201, is a tumor imaging agent.” NCT03906643 ↗ |
| Route | Intravenous | “HS-201 will be administered intravenously as a single dose” NCT03906643 ↗ |